Bone Biologics Corp Warrants
BBLGW
4 hedge funds and large institutions have $246K invested in Bone Biologics Corp Warrants in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$138K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$32.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.82K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $116K | +$138K | +5,516 | New |
|
|
EAM
2
Empery Asset Management
New York
| $100K | +$119K | +4,762 | New |
|
|
WAM
3
Warberg Asset Management
Winnetka,
Illinois
| $27K | +$32.4K | +1,300 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $3K | +$3.82K | +153 | New |
|
BBLGW Hedge Fund Activity: Q4 2021 in Review
4 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q4 2021, worth a combined $246K.
Buyers outnumbered sellers: 4 funds opened new BBLGW positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $138K.
- 4 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $246K of Bone Biologics Corp Warrants stock for Q4 2021.
- 4 funds opened new Bone Biologics Corp Warrants positions in Q4 2021 and 0 closed out, a net change of +4 holders.
- The largest Bone Biologics Corp Warrants buyer in Q4 2021 was Sabby Management, an estimated $138K added.
Based on aggregated 13F filings for Q4 2021.